New drug combo aims for deeper remission in young CLL patients

NCT ID NCT02251548

Ongoing Disease control Sponsor: Dana-Farber Cancer Institute Source: ClinicalTrials.gov ↗

Summary

This study is testing whether adding a newer targeted drug called ibrutinib to a standard chemotherapy combination (FCR) is safe and more effective for younger patients with CLL who have not yet received any treatment. The main goal is to see if this combination can lead to a deeper remission where no cancer cells can be detected in the bone marrow. The study enrolled 85 participants to evaluate the treatment's effectiveness and safety.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02215, United States
Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Duke University Medical Center

Durham, North Carolina, 27710, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
University of Kansas Cancer Center

Westwood, Kansas, 66205, United States
University of Miami Sylvester Comprehensive Cancer Center

Coral Gables, Florida, 33146, United States
University of Miami Sylvester Comprehensive Cancer Center

Deerfield Beach, Florida, 33442, United States
Unversity of Miami Sylvester Comprehensve Cancer Center

Miami, Florida, 33136, United States
West Michigan Cancer Center

Kalamazoo, Michigan, 49007, United States

Conditions

Explore the condition pages connected to this study.

CHRONIC LYMPHOCYTIC LEUKEMIA LEUKEMIA